SCHEMBL7188682

SCHEMBL7188682

N#Cc1ccc2c(c1)n(Cc1ccc(Cl)cc1)c(=O)n2[C@H]1CC[C@H](O)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HSD11B1 P28845 2/20 0.42
CCR2 P41597 1/20 0.39
MDM2 Q00987 2/20 0.39
DRD2 P14416 1/20 0.39
SLC6A4 P31645 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
TP53 P04637 1/20 0.38
OPRM1 P35372 2/20 0.38
C5AR1 P21730 3/20 0.38
P2RX3 P56373 2/20 0.37
CLPP Q16740 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PARG Q86W56 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188706 1.00 CYP3A4 (0.42) CYP3A4CYP2D6HSD11B1CCR2MDM2
SCHEMBL7183760 0.91 MTHFD2 (0.40) CYP3A4CYP2D6CCR2PRMT5WDR77
SCHEMBL7183765 0.91 MTHFD2 (0.40) CYP3A4CYP2D6CCR2PRMT5WDR77
SCHEMBL7176915 0.90 CYP3A4 (0.47) CYP3A4CYP2D6CCR2DRD2OPRM1
SCHEMBL7176913 0.90 CYP3A4 (0.47) CYP3A4CYP2D6CCR2DRD2OPRM1
SCHEMBL7188245 0.86 CYP3A4 (0.40) CYP3A4CYP2D6HSD11B1CCR2MDM2
SCHEMBL7188239 0.86 CYP3A4 (0.40) CYP3A4CYP2D6HSD11B1CCR2MDM2
SCHEMBL7182960 0.85 PDE7A (0.44) MDM2PRMT5WDR77TP53C5AR1
SCHEMBL7185263 0.85 PDE5A (0.47) MDM2PRMT5WDR77TP53
SCHEMBL7178544 0.85 PDE5A (0.47) MDM2PRMT5WDR77TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed